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TO THE EDITOR
Generalized pustular psoriasis (GPP)
is a rare disorder affecting about 2 per
million individuals in Europe (Augey
et al., 2006). This severe disease is
characterized by repeated flare-ups
of pustules and can be accompanied
by a potentially life-threatening multisy-
stemic inflammation. Recently, missense
mutations in IL36RN have been
identified in GPP patients from Tunisia
and Europe (Marrakchi et al., 2011;
Onoufriadis et al., 2011). In addition,
a stop mutation, a novel missense
mutation, and mutations affecting
splicing of exon 3 have been observed
in Japanese patients (Sugiura et al.,
2012; Farooq et al., 2013). IL36RN’s
product IL36RA antagonizing three
cytokines of the IL1-family (Blumberg
et al., 2010) and therapy with a
recombinant interleukin-1 receptor
antagonist (anakinra) being effective in
some GPP patients (Viguier et al., 2010)
independently support the role of
IL36RN as a disease-causing gene.
A group of 19 patients were recruited
at five German university hospitals and
one specialized dermatology hospital. In
all, 17 patients suffered from typical
symptoms of GPP, one patient from
psoriasis vulgaris (PsV) with repeated
flares of generalized grouped pustules
without fever (ID P18, Table 1), and
another one from PsV with pustules
(P19). The study, approved by the ethi-
cal committee of the University of
Erlangen, was conducted according to
the Declaration of Helsinki principles.
All patients/legal guardians gave written
informed consent. Patients were
screened for mutations in coding exons
2–5 of IL36RN by Sanger sequencing;
mutations were named according to
reference sequence NM_173170. In
cases of no point mutation/homozygous
mutations without available parents,
MLPA (multiplex ligation-dependent
probe amplification, MRC Holland,
(Schouten et al., 2002)) as a quanti-
tative analysis was performed with self-
designed oligonucleotides for coding
exons. The three-dimensional structure
of human IL36RA was modeled with
SwissModel (Guex et al., 2009) using
the high-resolution crystal structure of
murine IL-1F5 as a template (PDB
code: 1MD6; Dunn et al., 2003).
Promising variants possibly affecting
the structure of IL36RA were
generated with SwissModel (Guex
et al., 2009), selecting the lowest-
energy rotamer for each mutated side
chain. Structure analysis and visualiza-
tion was performed with RasMol
(Sayle and Milner-White, 1995).
The majority of GPP patients were
female (68.4%; Table 1). We identified
homozygous/compound heterozygous
variants in seven patients: four patients
were homozygous for p.His32Arg,
p.Pro76Leu, or p.Ser113Leu, and three
further individuals were compound
heterozygous for p.Ser113Leu and either
p.Arg48Trp, p.Glu94X, or p.Pro76Leu.
The stop mutation and the two missense
variants p.His32Arg and p.Pro76Leu
were, to our knowledge, previously
unreported, all affecting highly con-
served residues. p.Glu94X disrupted
the globular cytokine fold (Figure 1b).
The lack of the C-terminal half of the
domain caused the loss of two -sheets
and an important disulfide bond that
fixed the relative orientation of the N
and C terminus. Pro76 was located at a
loop position at which a leucine could
not be accommodated owing to steric
clashes (Figure 1e and f), causing struc-
tural changes of the respective loop and/
or decreased protein stability. In the
case of p.Arg48Trp, the wild type’s
arginine formed both cation–pi stacking
interactions and a hydrogen bond with
Tyr89 (Figure 1c). Because of its bulki-
ness, the side chain of W48 adopted a
different orientation in the mutant,
resulting in a loss of stabilizing interac-
tions with Tyr89 (Figure 1d). Ser113
stabilized the local geometry by a
hydrogen bond with Tyr116 that could
not be formed in the mutant p.Ser113-
Leu (Figure 1g and h). In addition, the
Leu113 side chain formed clashes with
the side chain of Cys70. Interestingly,
the same residue was also affected by
clashes upon p.Pro76Leu (Figure 1f),
suggesting similar structural effects.
In contrast, His32 was oriented toward
the solvent; therefore, p.His32Arg was
not expected to have a significant effect
on IL36RA structure/stability, but it pos-
sibly has an effect on the interaction with
its receptor. As its respective structure is
unknown to date, the prediction was
based on the crystal structure of the
homologous IL-1 in complex with
IL1R (Vigers et al., 1997). Gln32 of
IL-1—structurally equivalent to His32
of IL-36RA—formed tight interactions
with the IL1 receptor (Figure 1i),
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suggesting that the respective residue of
IL36RA could also be involved in receptor
binding. The structure of the IL1–IL1R
complex revealed that residue 48 is
also involved in receptor recognition
(Figure 1i), suggesting that mutation
p.Arg48Trp not only affects IL36RA stabi-
lity, but also affects receptor binding. Four
online prediction tools support damaging
effects of p.Arg48Trp, p.Pro76Leu, and
p.Ser113Leu, whereas the rare variant
p.His32Arg was predicted to be neutral
(Supplementary Table 1 online). Thus, we
cannot exclude that p.His32Arg is a rare,
non–disease-causing variant. Additional
functional validation studies of mutations
were beyond the scope of this work.
The mutations, to our knowledge
previously unreported, were not present
in 190 control individuals from a popu-
lation group corresponding to/being
similar to the carrier’s population. All
available unaffected parents of patients
(five families) tested as heterozygous
mutations carriers. In cases of homozy-
gous patients and unavailable parents,
quantitative analysis showed no evi-
dence for an undetected intragenic dele-
tion/duplication. The same was true for
P08 heterozygous for p.Ser113Leu and
11 patients lacking IL36RN mutations.
The most common European muta-
tion in our and other published cases
Table 1. Clinical data of patients
ID Gender
Age at
recruit-
ment
(years)
Age
of
onset
(years) PPP PsV PsA Tongue
Nail
dystro-
phy
Speci-
fications/
further
mani-
festations Triggering factors Ethnicity
Family
history
Rare non-
synonymous
variants in
IL36RN
Rare non-
synonymous
variants in
CARD14
P01 M 15 1/3      — Infections, medications Turkey c: 1st cousins
once
removed
hom. c.227C4
T/ p.Pro76Leu
(pþm het.)
—
P02 F 33 1    GT  — Urinary infections,
medications (novalgin,
penicillin), limited:
periodsþ stress
Iraq/
Germany
nc, PsV in
mother
hom. c.338C4
T/ p.Ser113Leu
het. c.599G4
A/ p.Ser200Asn
P03 M 36 14   þ ST  — Infections, stress Iraq nc, no
psoriasis
hom. c.95A4
G/ p.His32Arg
—
P04 F 46 16 þ  þ
(Small
finger
joints)
GT, ST  — Infections, antibiotics
(penicillin, amoxicillin),
aspirine, novalgin,
pregnancy, limited:
periods
Germany No psoriasis het. c.280G4
T/ p.Glu94X
(p)þ c.3384C4
T/ p.Ser113Leu
—
P05 F 46 17    GT, ST þ No fever Medication of
paracetamolþ codeine,
completion of therapy
with retinoid, stress
Germany/
Poland
nc, PsV in
brother
hom. c.338C4
T/ p.Ser113Leu
(pþm het.)
—
P06 F 48 40  þ   þ — Infections,
gastroenteritis, stress
Germany No psoriasis het c.142C4
T/ p.Arg48Trp
(p)þ c.338C4
T/ p.Ser113Leu
(m)
—
P07 F 27 1/3      — Antibiotics (penicillin
intra-abdominal),
paracetamol, infections,
stress, allergies
Germany/
Czech
Republic
PsV in father,
grandfather
þ in paternal
uncle
het. c.227C4
T/ p.Pro76Leu
(m)þ
c.3384C4T/
p.Ser113Leu (p)
—
P08 M 55 10 (PsV),
55 (GPP)
 þ  ST  1st episode
with
GPPþ cardio-
myopathy
Unknown Germany No psoriasis het. c.338C4T/
p.Ser113Leu
het. c.349G4
A/ p.Gly117Ser
þ c.2476C4
T/ p.Arg826Trp
P09 F 38 3     þ Regular
episodes
(4 / year)
Infections, completion of
therapy with cortisone/
MTX/retinoid,
pregnancy, stress; in the
past:
red wine
Germany PsV in
mother
None —
P10 F 39 5      — Stress Turkey No psoriasis None —
P11 F 56 9  þ þ   — Antibiotics
(sulfonamides), stress
Germany PsV in father
þ grandfather
None —
P12 F 59 16  þ  GT þ Cholangitis Infections, pain
medication
Germany/
Poland
No psoriasis None —
P13 M 42 17      — Infections, bronchitis,
stress
Germany PsV in
mother/
siblings
None —
P14 F 56 27      — Stress, pregnancy?
(first manifestations 6
months after giving birth)
Germany No psoriasis None het. c.206G4
A/ p.Arg69Gln
P15 F 66 41  þ    No fever Unknown Germany PsV in
mother/son
None —
P16 M 68 45      — Unknown Germany No psoriasis None —
P17 F 62 49   þ  þ — Stress Finland/
Germany
No psoriasis None —
P18 F 77 69      — Unknown Germany No psoriasis None —
P19 M 78 72  þ    With pustules Unknown Germany No psoriasis None —
Abbreviations: c, consanguinity; F, female; GT, geographic tongue; het., heterozygous for; hom., homozygous for; m, maternal; M, male; nc, no consanguinity;
p, paternal; PPP, palmoplantar psoriasis; PsA, psoriatic arthritis; PsV,psoriasis vulgaris; ST, scrotal tongue; þ , present;  , not present.
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was p.Ser113Leu. Interestingly, this
mutation was also present in P02 with
one parent from Iraq. Similarly, p.Pro76-
Leu was present in a German/Czech and
a Turkish patient.
Phenotype–genotype correlation
including published cases was difficult
owing to different mutations in few
carriers. A significant difference in age
of onset between carriers of two muta-
tions and noncarriers of mutations was
not observed (P¼0.08; excluding P08
(one mutation)). The widely varying age
of onset (1–51 years of age) in four
homozygous carriers of the most com-
mon European mutation p.Ser113Leu
(two taken from the previous publication
(Onoufriadis et al., 2011)) can currently
not be explained. An additional coding
variant (p.Ser200Asn, according to
NM_024110) in CARD14, more
recently shown to be relevant for the
pathogenesis of PsV and GPP (Jordan
et al., 2012a, b), was identified in P02,
who developed disease at age 1 year, but
not in P05, whose disease manifested
at the age of 17 years (Supplementary
Table 2 online). p.Ser200Asn was shown
to be functionally relevant (Jordan et al.,
2012a) and is a potential modifier for
disease onset/severity. Sanger sequencing
of CARD14 in another 17 patients
revealed three rare variants (rare allele
o1%) in two patients (Table 1, Supple-
mentary Table 2 online): p.Arg69Gln in
P14 is, to our knowledge, a previously
unreported variant, also not reported in
4,300 exomes (http://evs.gs.washingto-
n.edu/EVS/). Located in the CARD
domain, it is predicted to be damaging
by various analysis tools. We therefore
regard it as a contributing factor to P14’s
GPP. Described to cause autosomal
dominant inherited PsV (Jordan et al.,
2012b), P08’s mutation p.Gly117Ser is
probably responsible for long-existing
PsV, whereas the additional hetero-
zygous IL36RN mutation may have
induced his first GPP episode.
Our rate of 38.9% IL36RN mutations
provides further evidence that GPP is
heterogenous. Anakinra is an effective
treatment in some patients with GPP, and
treatment success may be related to the
presence of IL36RN mutations. As such,
revealing the molecular basis of GPP in
single patients may be clinically impor-
tant for therapeutic decision making.
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Figure 1. Molecular modeling of mutations in IL36RA. (a) Model of IL36RA’s structure highlighting four of
the amino acids found to be exchanged in the present study. (b) Effect of p.Glu94X lacking the C-terminal
half (blue) of the globular cytokine domain. Red/magenta arrows indicate a loss of two b-sheets/of a
disulfide bond, respectively. (c, d) Effect of p.Arg48Trp. (c) Wild-type-allele Arg48 (‘‘stick’’) interacts with
Tyr89 (‘‘space-filled’’) via cation–pi interactions and by a hydrogen bond (green line). (d) Trp48 adopts
a different side-chain orientation, resulting in a loss of interactions with Tyr89. (e, f) Effect of p.Pro76Leu.
(e) Pro76 is located at a turn at which a leucine cannot be accommodated, resulting in clashes with Cys70
and Leu133 (f, red arrows). (g, h) Effect of p.Ser113Leu. (g) Ser113 forms a hydrogen bond with Tyr116
(green line) that cannot be formed in the mutant. (h) Leu113 forms clashes (red arrow) with the side chain
of Cys70 in a similar manner as p.Pro76Leu (f). (i) Structure of IL-1 (blue) in a complex with IL1R (green).
Residues Gln32, Gln48, Pro78, and Ser114 are highlighted in red and correspond to residues His32,
Arg48, Pro76, and Ser113 of IL36RA, respectively.
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TO THE EDITOR
Generalized pustular psoriasis (GPP;
OMIM 614204) is a severe type of
psoriasis characterized by widespread
erythematous skin and sterile pustules.
The acute onset is typically associated
with high-grade fever, rigor, and toxi-
city. Psoriasis vulgaris (PV; OMIM
177900) is the most common form of
psoriasis, which is an immune-mediated
inflammatory skin disease with scaly
and well-demarcated red plaques.
Although GPP is traditionally classified
as a variant of PV, the common mech-
anisms of pathogenesis remain unclear
(Setta-Kaffetzi et al., 2013).
Recently, a homozygous loss-of-
function mutation in IL-36RN, L27P,
was first identified in GPP patients
(Marrakchi et al., 2011). On the other
hand, different mutations were found
by exome sequencing on unrelated
individuals with GPP in Caucasians
(Onoufriadis et al., 2011). Of note,
our previous study in 10 Chinese
GPP patients showed that only one
known polymorphism, c.227C4T, was
identified in one patient (Li et al.,
2012). We also found the c.115þ
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